Major Developments: LEADS BIOLABS-B (09887) will prioritize the clinical development of LBL-047 for Sjögren's syndrome, systemic lupus erythematosus, and dermatomyositis. ASCLETIS-B (01672) will present data from multiple projects at the 33rd European Congress on Obesity (ECO 2026). RIBOLIFE-B (06938) has achieved a key milestone in its R&D collaboration with Boehringer Ingelheim. Simeere (02096) announced that SIM0613 (an LRRC15 antibody-drug conjugate) has received a drug clinical trial approval notice from the National Medical Products Administration. Yidu Tech (02158) subsidiary successfully won the bid for the implementation of Dr. Buddy and will provide support and maintenance. Sinohyenergy (02582) subsidiary intends to supply a full set of equipment for a 300MW new energy coupled green power project to Jiujiang Power Construction (Shaanxi). TESSON HOLDINGS (01201) subsidiary signed a memorandum of understanding with DST to establish a joint venture aimed at building a new energy charging and battery swap network in Hong Kong, with the first phase involving the construction of 10 multi-functional battery swap stations. Man Shing Group Holdings (01451) received a mandatory unconditional cash offer from Executive Director Chung Kwok Keung at a discount of approximately 34.96%; trading will resume on May 6.
Operational Performance: Meitu (01357) reported first-quarter revenue from its core business, imaging and design products, of RMB 852 million, a year-on-year increase of 34.3%. Seres (09927) reported total vehicle sales of 123,900 units for the first four months, a year-on-year increase of 19.02%. HSBC Holdings (00005) released its first-quarter results, with net interest income of $8.9 billion, an 8% year-on-year increase.
Comments